NCT02376543 is a NA clinical trial of 19 Gauge EUS FNA BNX in Pancreatic Neoplasms, sponsored by Parkview Health.

Who is sponsoring NCT02376543?

NCT02376543 is sponsored by Parkview Health.

What drugs are being tested in NCT02376543?

Interventions in NCT02376543: 19 Gauge EUS FNA BNX, 22 Gauge EUS FNA BNX.

What condition does NCT02376543 study?

NCT02376543 studies Pancreatic Neoplasms.

Is NCT02376543 still recruiting?

NCT02376543 is currently withdrawn. Last updated 29 September 2020.

Last reviewed 2020-09-29 · How we verify

NCT02376543

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison Study in Pancreatic Fiducial Placement

Withdrawn NA Last updated 29 September 2020

What this trial tests

NA trial testing 19 Gauge EUS FNA BNX in Pancreatic Neoplasms. Withdrawn.

Timeline

6 March 2015

Primary endpoint
15 March 2019

15 March 2019

Quick facts

Lead sponsor	Parkview Health
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	6 March 2015
Primary completion	15 March 2019
Estimated completion	15 March 2019
Sites	1 location across United States

Drugs / interventions tested

19 Gauge EUS FNA BNX
22 Gauge EUS FNA BNX

Conditions studied

Pancreatic Neoplasms — all drugs for Pancreatic Neoplasms →

Sponsor

Parkview Health

Who can join

18 and older, any sex, with Pancreatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparison Study between 19 gauge EUS FNA BNX Needle vs. 22 gauge EUS FNA BNX Needle in Pancreatic Fiducial Placement To Treat Pancreatic Cancer

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pancreatic Neoplasms

Currently open trials in the same condition.

NCT07504471 — Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhib · Phase 2 · recruiting
NCT07139236 — Preoperative EUS Elastography for Pancreatic Texture and POPF Prediction After PD · recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT06939023 — Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3) · NA · recruiting
NCT06953193 — Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia · NA · recruiting

Other Parkview Health trials

Trials by the same sponsor.

NCT06239610 — DrIFT 2 Study: Displacement in Feeding Tubes · NA · completed
NCT04558034 — The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer · NA · terminated
NCT03245580 — Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease) · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02376543 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Parkview Health
Last refreshed: 29 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02376543.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing